Rapid response of plasmacytomas to lenalidomide plus low‐dose dexamethasone therapy in a patient with relapsed multiple myeloma

Fukushima, Toshihiro; Nakamura, Takuji; Iwao, Haruka; Umehara, Hisanori

doi:10.1002/ajh.22110

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature review identified a total of 111 previously reported cases in 68 articles regarding orbital involvement in patients with systemic MM (Table 2). 4,6-61…”

Section: Resultsmentioning

confidence: 99%

Orbital Involvement in Multiple Myeloma

Shoji

Chen

Topilow

et al. 2023

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: To characterize clinical and radiographic features, management, and outcomes of patients with orbital involvement of multiple myeloma (MM). Methods: A retrospective chart review identified patients with MM and orbital involvement confirmed by histopathology at a single institution between 1995 and 2021. A comprehensive literature review was performed via PubMed to identify all previously reported cases of orbital MM. Results: Retrospective review identified 7 patients (43% male, mean age 68.7 years). Presenting symptoms included proptosis and diplopia. Orbital lesions were primarily located laterally (42.8%) with associated extraocular muscle (57.1%) or lacrimal gland (42.9%) involvement. Five patients (71.4%) had a previous diagnosis of systemic MM. Six patients received chemoradiation (85.7%). All patients had improvement of orbital disease with 2 patients deceased due to disease at follow-up (mean 8.9 months). Literature review identified 111 cases (46.8% male, mean age 58.6 years). 48.6% presented with orbital disease as the first manifestation of systemic MM. Lesions were most commonly located superolaterally (20.2%) with extraocular muscle infiltration (25.2%), lacrimal gland involvement (7.2%), and orbital bony destruction (39.6%). Treatments included chemoradiation, chemotherapy, or radiation alone. Approximately half (51.4%) of patients experienced improvement in orbital disease following treatment, and 48.6% were deceased at follow-up (mean 20.1 months). Conclusions: This study provides a new retrospective study and updated comprehensive literature review regarding orbital MM. Given its poor prognosis, characterization of orbital MM is essential for early diagnosis. Orbital MM is often unilateral, located superolaterally, and may represent the first manifestation of systemic disease. Treatment includes chemotherapy and radiation, which may improve orbital disease; however, the overall prognosis remains poor.

show abstract

“…Literature review identified a total of 111 previously reported cases in 68 articles regarding orbital involvement in patients with systemic MM (Table 2). 4,6-61…”

Section: Resultsmentioning

confidence: 99%

Orbital Involvement in Multiple Myeloma

Shoji

Chen

Topilow

et al. 2023

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…For their 18 reported cases, the overall response was 61%, including a complete disappearance in 44% of these cases. It was assumed that lenalidomide could have direct anti-proliferative mechanisms on myeloma cells irrespective of its existence in the bone marrow stroma or other tissue microenvironments [23]. Angiogenesis is promoted in plasmacytoma tissue, such that lenalidomide might exhibit anti-tumor activity especially through its anti-angiogenic effects [24].…”

Section: Discussionmentioning

confidence: 99%

Rapid Disappearance of Testicular Plasmacytoma after Treatment with Lenalidomide plus Dexamethasone

Hagihara¹,

Inoue²,

Jiang³

et al. 2012

OJPathology

View full text Add to dashboard Cite

We describe a rare case of testicular plasmacytoma first manifesting as a relapse. The patient was initially diagnosed with IgG-λ-type multiple myeloma and treated with melphalan and prednisolone plus bortezomib, achieving a complete remission. Four months later, his left scrotum began to swell and pathological investigation of a needle biopsy specimen revealed proliferation of plasma cells expressing IgG-λ, confirming myeloma recurrence. However, bone marrow aspiration samples showed no significant increase in myeloma cells and there was no skewed deviation of the   ratio on flow-cytometric analysis. The extramedullary tumors disappeared completely soon after treatment with lenalidomide plus dexamethasone, and the patient was judged to be in very good partial remission based on negative M-protein results by serum immunoelectrophoresis. This is the first report, to our knowledge, describing complete disappearance of a testicular plasmacytoma after treatment with lenalidomide as the key-drug.

show abstract

Rapid response of plasmacytomas to lenalidomide plus low‐dose dexamethasone therapy in a patient with relapsed multiple myeloma

Cited by 2 publications

References 25 publications

Orbital Involvement in Multiple Myeloma

Orbital Involvement in Multiple Myeloma

Rapid Disappearance of Testicular Plasmacytoma after Treatment with Lenalidomide plus Dexamethasone

Contact Info

Product

Resources

About